Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
TransCode Therapeutics, Inc. - Common Stock
(NQ:
RNAZ
)
8.050
-0.350 (-4.17%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TransCode Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
The trading volume of these stocks is deviating from the norm in today's session.
January 29, 2025
Which stocks have an unusual volume on Wednesday?
Via
Chartmill
How Is The Market Feeling About TransCode Therapeutics?
January 29, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 29, 2025
Via
Benzinga
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
January 28, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
Peering Into TransCode Therapeutics's Recent Short Interest
December 12, 2024
Via
Benzinga
Why TransCode Therapeutics (RNAZ) Stock Is Diving
December 02, 2024
TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split.
Via
Benzinga
Why Transcode Therapeutics (RNAZ) Stock Is Moving
November 25, 2024
Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's approval of a 1-for-33 reverse stock split.
Via
Benzinga
Unusual volume stocks are being observed in Tuesday's session.
January 28, 2025
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via
Chartmill
These stocks are moving in today's session
January 28, 2025
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
The market is filled with gapping stocks in Tuesday's session.
January 28, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
On Friday, there are stocks with unusual volume. Let's take a look.
January 24, 2025
These stocks have an unusual volume in today's session
Via
Chartmill
TransCode Therapeutics Shares Are Surging Today: What's Going On?
January 24, 2025
TransCode Therapeutics Inc. (NASDAQ: RNAZ) shares are moving higher Friday after the company announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with its lead...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 18, 2024
Via
Benzinga
Crude Oil Gains Over 1%, General Mills Shares Fall
December 18, 2024
Via
Benzinga
Exposures
Fossil Fuels
Dow Surges 150 Points, US Current Account Deficit Widens In Q3
December 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
November 29, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
November 27, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
November 25, 2024
Split designed to achieve compliance with Nasdaq minimum bid price requirements
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Open Letter to Shareholders
November 12, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
November 05, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 23, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
October 10, 2024
Via
Benzinga
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
October 10, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 03, 2024
Via
Benzinga
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 17, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
September 10, 2024
Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 05, 2024
Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.